Advertisement
Advertisement
CYTK
Cytokinetics Inc.
56.18
USDSponsored
+1.04
+1.89%
Nov 10, 15:59 UTC -5
Closed
After-Market
56.48
+0.30
+0.53%
Cytokinetics Inc. (CYTK) Earnings
CYTK Earnings Reports
Positive Surprise Ratio
CYTK beat 17 of 43 last estimates.
40%
Next Report
Date of Next Report
Feb 22, 2027
Estimate for Q4 26 (Revenue/ EPS)
$65.17M
/-$1.46
Implied change from Q3 26 (Revenue/ EPS)
+37.04%
/+6.57%
Implied change from Q4 25 (Revenue/ EPS)
+267.05%
/-2.67%
Cytokinetics Inc. earnings per share and revenue
On Nov 04, 2026, CYTK reported earnings of -1.37 USD per share (EPS) for Q3 26, beating the estimate of -1.48 USD, resulting in a 7.66% surprise. Revenue reached 47.56 million, compared to an expected 42.72 million, with a 11.33% difference. The market reacted with a -12.66% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -1.46 USD, with revenue projected to reach 65.17 million USD, implying an increase of 6.57% EPS, and increase of 37.04% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Legend Biotech Corporation - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
$0.00
Actual
$0.13
Surprise
+9,900.00%
Hemab Therapeutics Holdings, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.53
Actual
-$0.57
Surprise
-8.51%
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
MaxCyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.07
Actual
-$0.05
Surprise
+36.79%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
iBio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q1 27
Estimate
-$0.07
Actual
-$0.05
Surprise
+33.16%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
FAQ
What were Cytokinetics Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Cytokinetics Inc. reported EPS of -$1.37, beating estimates by 7.66%, and revenue of $47.56M, 11.33% above expectations.
How did the market react to Cytokinetics Inc.'s Q3 2026 earnings?
The stock price moved down -12.66%, changed from $63.60 before the earnings release to $55.55 the day after.
When is Cytokinetics Inc. expected to report next?
The next earning report is scheduled for Feb 22, 2027.
What are the forecasts for Cytokinetics Inc.'s next earnings report?
Based on --
analysts, Cytokinetics Inc. is expected to report EPS of -$1.46 and revenue of $65.17M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.